Sean F. Scanlan Treace Medical Concepts, Inc. (TMCI) insider trading activity

Sean F. Scanlan is Chief Innovation Officer of TREACE MEDICAL CONCEPTS, INC.. Currently has a direct ownership of 364,081 shares of TMCI, which is worth approximately $3.08 Million. The most recent transaction as insider was on Mar 17, 2025, when has been sold 50,000 shares (Common Stock) at a price of $7.97 per share, resulting in proceeds of $398,500. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 364K

61.63% 3M change

281.54% 12M change

Total Value Held $3.08 Million

Sean F. Scanlan Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Mar 17 2025	SELL Open market or private sale	$398,500 $7.97 p/Share	50,000 Reduced 12.07%	364,081 Common Stock
Mar 17 2025	BUY Exercise of conversion of derivative security	$52,500 $1.05 p/Share	50,000 Added 10.77%	414,081 Common Stock
Mar 10 2025	SELL Payment of exercise price or tax liability	-	1,396 Reduced 0.38%	364,081 Common Stock
Mar 08 2025	SELL Payment of exercise price or tax liability	-	401 Reduced 0.11%	365,477 Common Stock
Jan 22 2025	BUY Grant, award, or other acquisition	-	140,625 Added 27.76%	365,878 Common Stock
Jan 10 2025	SELL Payment of exercise price or tax liability	-	4,821 Reduced 2.1%	225,253 Common Stock
Sep 12 2024	BUY Exercise of conversion of derivative security	$3,375 $0.1 p/Share	33,750 Added 11.89%	250,074 Common Stock
Aug 09 2024	BUY Grant, award, or other acquisition	-	120,900 Added 35.85%	216,324 Common Stock
Mar 10 2024	SELL Payment of exercise price or tax liability	-	1,396 Reduced 1.44%	95,424 Common Stock
Mar 08 2024	SELL Payment of exercise price or tax liability	-	389 Reduced 0.4%	96,820 Common Stock
Jan 10 2024	BUY Grant, award, or other acquisition	-	65,025 Added 40.08%	97,209 Common Stock
Nov 02 2023	SELL Payment of exercise price or tax liability	-	211 Reduced 0.65%	32,184 Common Stock
May 16 2023	SELL Open market or private sale	$636,000 $25.44 p/Share	25,000 Reduced 43.56%	32,395 Common Stock
May 16 2023	BUY Exercise of conversion of derivative security	$2,500 $0.1 p/Share	25,000 Added 30.34%	57,395 Common Stock
Mar 10 2023	BUY Grant, award, or other acquisition	-	22,925 Added 41.44%	32,395 Common Stock
Mar 09 2023	SELL Open market or private sale	$12,327 $24.41 p/Share	505 Reduced 5.06%	9,470 Common Stock
Feb 15 2023	SELL Open market or private sale	$542,250 $21.69 p/Share	25,000 Reduced 71.48%	9,975 Common Stock
Feb 15 2023	BUY Exercise of conversion of derivative security	$2,500 $0.1 p/Share	25,000 Added 41.68%	34,975 Common Stock
Jan 12 2023	SELL Open market or private sale	$639,250 $25.57 p/Share	25,000 Reduced 71.48%	9,975 Common Stock
Jan 12 2023	BUY Exercise of conversion of derivative security	$2,500 $0.1 p/Share	25,000 Added 41.68%	34,975 Common Stock
Nov 14 2022	SELL Open market or private sale	$606,750 $24.27 p/Share	25,000 Reduced 71.48%	9,975 Common Stock
Nov 14 2022	BUY Exercise of conversion of derivative security	$2,500 $0.1 p/Share	25,000 Added 41.68%	34,975 Common Stock
Oct 24 2022	BUY Grant, award, or other acquisition	-	3,400 Added 25.42%	9,975 Common Stock
Mar 08 2022	BUY Grant, award, or other acquisition	-	6,575 Added 50.0%	6,575 Common Stock
Mar 02 2022	SELL Open market or private sale	$520,500 $20.82 p/Share	25,000 Reduced 100.0%	0 Common Stock

SFS

Sean F. Scanlan

Chief Innovation Officer

Ponte Vedra, FL

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells TMCI shares.

Notify only if

Value

Insider Trading

Get notified when an Treace Medical Concepts, Inc. insider buys or sells TMCI shares.

Notify only if

Operation

Value

Type

News

Receive news related to TREACE MEDICAL CONCEPTS, INC.

Track Activities on TMCI

Account